Columnist Samuel Kirton attended the Pulmonary Fibrosis Foundation's Summit 2025, where the group's five-year strategic plan was unveiled.

Treatment with Endeavor Biomedicines’ experimental oral therapy ENV-101 (taladegib) improved lung function in people with IPF ...

A Phase 2 trial testing experimental therapy CAL101 in people with IPF is recruiting participants. CAL101 has been granted ...

This Veterans Day, columnist Samuel Kirton writes about the PACT Act, which expanded coverage for veterans exposed to toxic substances.

For pulmonary fibrosis patients, lung transplant is often the best choice for extending life and improving quality of life. Because PF is a progressive disease with no current cure, the lungs ...

Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The ...

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

The National Institutes of Health has awarded $219,000 to fund a project at the University of Texas at Tyler aimed at developing a treatment for radiation-induced pulmonary fibrosis (PF) which can ...

Fast shallow breathing (tachypnea) is one of several breathing difficulties experienced by pulmonary fibrosis (PF) patients. Breathing problems are common in PF because the disease causes progressive ...